Dexmedetomidine is used to sedate patients who are on mechanical ventilation in intensive care units, and to provide sedation during medical procedures. It helps keep patients calm and reduces anxiety while allowing them to be easily awakened.[2] Precedex is currently approved and in use across 157 indications[4].[1]
Precedex is one of 2003 small molecule programs targeting Glioma. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Precedex
Halaven
Trodelvy
Avastin
Lexiscan
Voltaren
Effexor
Avastin
Systemic Therapy
Apatinib Mesylate
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Total Intravenous Anesthesia
NCT07271459
Dexmedetomidine
NCT07462195
Dexmedetomidine
NCT06639659
Agitation
NCT06620393
Functional Endoscopic Sinus Surgery
NCT07213037
Extracorporeal Membrane Oxygenation
NCT03593408
Clinical
Regulatory
Oct 21, 2015
DEXMEDETOMIDINE HYDROCHLORIDE
NDA NDA206628
Jan 31, 2020
PRECEDEX
NDA NDA021038
Apr 5, 2022
IGALMI
NDA NDA215390
Sources
Details
Patent Cliff
Jan 4, 2032
Earliest patent expiration — generic entry possible after this date